Cabaletta Bio Q2 2026: $51M Net Loss, Going Concern Warning Despite $225M Cash
CABA has more than doubled off its 52-week low of $1.26.
Summary
Cabaletta Bio's Q2 2026 10-Q shows a widening net loss and a going concern warning, despite a cash position that funds operations into mid-2027. The filing also details outstanding warrants and recent financing activities.
Key Events · Earnings and Guidance · CABA
-
Q2 Net Loss Widens
Net loss of $51.0 million for Q2 2026, compared to $45.1 million in Q2 2025, driven by higher R&D spending on rese-cel clinical trials and manufacturing.
-
Going Concern Warning Reiterated
Management states substantial doubt exists about the company's ability to continue as a going concern, despite $225.1 million in cash and cash equivalents as of June 30, 2026.
-
Cash Runway into Mid-2027
The company expects current cash to fund operations into mid-2027, but will need additional capital to complete clinical development and commercialization.
-
Warrant Overhang
47,815,090 common stock warrants with a $2.50 exercise price expire on September 12, 2026; if exercised for cash, they would provide approximately $120 million in gross proceeds but cause significant dilution.
Analysis · CABA · Life Sciences
Cabaletta Bio reported a $51.0 million net loss for Q2 2026, up from $45.1 million a year earlier, while holding $225.1 million in cash. The company reiterated that substantial doubt exists about its ability to continue as a going concern, even though its cash runway extends into mid-2027. The filing also reveals 47.8 million outstanding warrants expiring September 12, 2026, which could add significant dilution if exercised.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CABA was trading at $2.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $464.7M. The 52-week trading range was $1.26 to $4.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.